查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790445

美国生物模拟市场规模、份额和趋势分析报告，按产品、应用、治疗领域、部署模型、定价模式、最终用途和细分趋势划分：2025 年至 2030 年

U.S. Biosimulation Market Size, Share & Trends Analysis Report By Offering (Software, Services), By Application, By Therapeutic Area, By Deployment Model, By Pricing Model, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国生物模拟市场规模与趋势

预计 2024 年美国生物模拟市场价值将达到 17.8 亿美元，预计 2025 年至 2030 年的复合年增长率为 16.2%。

这一成长的关键驱动力在于，旨在降低药物开发成本和缩短开发週期的In Silico模拟建模和模拟工具的应用日益广泛。随着新药上市平均成本的持续上升，製药和生物技术公司正在利用生物模拟技术来优化临床试验计划、预测药物交互作用，并在研发早期识别潜在的安全隐患。精准医疗日益受到重视，以及对患者个人化给药策略的需求，进一步推动了对药理计量学和基于生理的药物动力学 (PBPK) 建模的需求。

随着医疗保健产业逐渐转向更个人化的治疗策略，对能够准确模拟患者特定治疗反应的工具的需求日益增长。生物模拟技术使研究人员能够开发出考虑个体间基因差异的详细模型，从而预测患者对特定药物和治疗方案的反应。这种方法可以根据每位患者的独特情况量身定制治疗方法，从而提高疗效并减少副作用。药物基因体学组学领域的扩张推动了美国医疗保健产业对能够将基因数据整合到预测模型中的先进生物模拟工具的需求。

人工智慧和机器学习的进步显着提升了生物模拟工具的功能。这些技术能够更准确、更有效率地模拟生物过程，使研究人员能够准确预测药物交互作用和疗效。将人工智慧和机器学习整合到生物模拟平台中，将有助于开发个人化医疗方法，从而根据患者的个别情况量身定制治疗方案。这些技术协同效应正在推动生物模拟在美国药物开发过程中的应用。

此外，美国药物管理局（FDA）的积极监管支持也推动了市场成长，该机构越来越多地接受生物模拟数据作为核准提交的一部分。生技药品和基因治疗方法、细胞疗法等复杂疗法的兴起也促进了市场扩张，因为这些治疗方法通常需要先进的建模方法来评估疗效和安全性。此外，人工智慧和机器学习与生物模拟平台的整合正在提高模型的准确性和可扩展性，使这些工具在整个药物开发生命週期中更易于使用且更有价值。

新冠疫情衝击了美国市场，加速了对模拟软体和服务的需求，以支持候选疫苗的快速开发和测试。例如，2020年8月，美国生物模拟领域的参与企业Certara与多家製药公司合作开发了一种新的生物模拟工具，利用虚拟患者和临床测试，简化了针对不同患者群体的候选疫苗的开发。这项创新旨在在现实世界的临床试验开始之前提供关键见解，从而提高疫苗开发的效率和效果。这项新功能已被整合到Certara的定量系统药理学（QSP）平台中，并凸显了生物模拟在美国医疗体系的疫情防治工作中日益增长的重要性。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 美国生物模拟市场分析工具：PESTEL
    • 政治与法律
    • 经济与社会
    • 科技
    • 环境
    • 社会
  • 科技趋势
  • 使用案例和见解
  • 美国生物模拟市场分析工具：波特五力分析
  • COVID-19影响分析

第四章美国生物模拟市场（依产品、估价和趋势分析）

  • 美国生物模拟市场：提供变异分析
  • 美国生物模拟市场：产品细分仪表板
  • 2024 年和 2030 年产品趋势和市场占有率分析
  • 透过提供
  • 软体
    • 分子建模与模拟软体
    • 临床试验设计软体
    • PK/PD建模和模拟软体
    • Pbpk建模与模拟软体
    • 毒性预测软体
    • 其他软体
  • 服务
    • 合约服务
    • 咨询
    • 其他（实施、培训、支援）

第五章：美国生物模拟市场的应用、预测与趋势分析

  • 美国生物模拟市场：应用趋势分析
  • 美国生物模拟市场：应用细分仪表板
  • 2024 年和 2030 年应用趋势和市场占有率分析
  • 按用途
  • 药物研发
  • 疾病模型
  • 其他（精准医疗、毒理学）

第六章：美国生物模拟市场（依治疗领域、估价和趋势分析）

  • 美国生物模拟市场：治疗领域差异分析
  • 美国生物模拟市场：治疗领域细分仪表板
  • 2024 年和 2030 年治疗领域趋势和市场占有率分析
  • 按治疗领域
  • 肿瘤学
  • 心血管疾病
  • 感染疾病
  • 神经系统疾病
  • 其他的

第七章：美国生物模拟市场（按部署模型、估计和趋势分析）

  • 美国生物模拟市场：部署模型波动分析
  • 美国生物模拟市场：部署模型细分仪表板
  • 2024 年和 2030 年部署模型趋势和市场占有率分析
  • 按部署模型
  • 云端基础
  • 本地
  • 混合模式

第八章：美国生物模拟市场：定价模式的估算与趋势分析

  • 美国生物模拟市场：定价模式波动分析
  • 美国生物模拟市场：定价模式细分仪表板
  • 2024 年和 2030 年定价模式趋势和市场占有率分析
  • 按定价模式
  • 基于许可证的模型
  • 订阅模式
  • 基于服务的模型
  • 计量收费模式

第九章美国生物模拟市场：按最终用途的估计和趋势分析

  • 美国生物模拟市场：最终用途差异分析
  • 美国生物模拟市场：最终用途细分仪表板
  • 2024 年和 2030 年最终用途趋势和市场占有率分析
  • 按最终用途
  • 生命科学公司
  • 学术研究机构
  • 其他（CRO/CDMO、监管机构）

第十章 竞争格局

  • 公司分类
  • 2024年企业市场地位/份额分析
  • 企业市场占有率分析
  • 公司简介/上市公司
    • Certara, USA.
    • Dassault Systemes
    • Advanced Chemistry Development
    • Simulation Plus
    • Schrodinger, Inc.
    • Chemical Computing Group ULC
    • Physiomics Plc
    • Rosa & Co. LLC
    • BioSimulation Consulting Inc.
    • Genedata AG
    • Instem Group of Companies
    • PPD, Inc.
    • Yokogawa Insilico BIoTechnology GmbH
Product Code: GVR-4-68040-674-2

U.S. Biosimulation Market Size & Trends:

The U.S. biosimulation market size was estimated at USD 1.78 billion in 2024 and is projected to grow at a CAGR of 16.2% from 2025 to 2030. This growth is primarily driven by the increasing adoption of in silico modeling and simulation tools to reduce drug development costs and timelines. With the average cost of bringing a new drug to market continuing to rise, pharmaceutical and biotech companies are leveraging biosimulation to optimize clinical trial designs, predict drug interactions, and identify potential safety concerns early in the R&D process. The growing emphasis on precision medicine and the need for patient-specific dosing strategies further boost the demand for pharmacometrics and physiologically based pharmacokinetic (PBPK) modeling.

As the healthcare industry moves toward more tailored treatment strategies, a growing demand exists for tools that accurately model patient-specific therapy responses. Biosimulation enables researchers to develop detailed models accounting for genetic variations among individuals, helping predict how different patients respond to particular drugs or treatment plans. This approach improves treatment effectiveness while reducing adverse effects by customizing therapies to each patient's unique profile. The expanding field of pharmacogenomics highlights the critical need for advanced biosimulation tools capable of incorporating genetic data into predictive models within the U.S. healthcare landscape.

Advancements in AI and ML are significantly enhancing the capabilities of biosimulation tools. These technologies allow for more accurate and efficient simulations of biological processes, enabling researchers to predict drug interactions and outcomes precisely. Integrating AI and ML into biosimulation platforms facilitates the development of personalized medicine approaches, where treatments are tailored to individual patient profiles. This technological synergy is driving the adoption of biosimulation in drug development processes across the U.S.

Moreover, favorable regulatory support from the U.S. FDA, which increasingly accepts biosimulation data as part of regulatory submissions, enhances market growth. The rise of biologics and complex therapies, such as gene and cell therapies, has also contributed to the market expansion, as these treatments often require advanced modeling approaches to evaluate efficacy and safety. Moreover, the integration of artificial intelligence and machine learning into biosimulation platforms is enhancing model accuracy and scalability, making these tools more accessible and valuable across the drug development lifecycle.

The COVID-19 pandemic impacted the U.S. market, accelerating the demand for biosimulation software and services to support vaccine candidates' rapid development and testing. For instance, in August 2020, Certara, a player in the U.S. biosimulation sector, partnered with several pharmaceutical companies to develop a new biosimulation tool to streamline vaccine candidate development across diverse patient populations using virtual patients and clinical trials. This innovation aimed to provide critical insights before initiating real-world studies, enhancing the efficiency and effectiveness of vaccine development. This new capability was integrated into Certara's Quantitative Systems Pharmacology (QSP) platform, highlighting the growing importance of biosimulation in pandemic response efforts within the U.S. healthcare system.

U.S. Biosimulation Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. biosimulation market report based on offering, application, therapeutic area, deployment model, pricing model, and end-use.

  • Offering Outlook (Revenue, USD Million, 2018 - 2030)
  • Software
    • Molecular Modeling & Simulation Software
    • Clinical Trial Design Software
    • PK/PD Modeling and Simulation Software
    • Pbpk Modeling and Simulation Software
    • Toxicity Prediction Software
    • Other Software
  • Services
    • Contract Services
    • Consulting
    • Other (Implementation, Training, & Support)
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Drug Discovery & Development
  • Disease Modeling
  • Other (Precision Medicine, Toxicology)
  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurological Disorders
  • Others
  • Deployment Model Outlook (Revenue, USD Million, 2018 - 2030)
  • Cloud-based
  • On-premise
  • Hybrid Model
  • Pricing Model Outlook (Revenue, USD Million, 2018 - 2030)
  • License-based Model
  • Subscription-based Model
  • Service-based Model
  • Pay Per Use Model
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Life Sciences Companies
  • Academic Research Institutions
  • Others (CROs/CDMOs, Regulatory Authorities)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Biosimulation Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Offering segment outlook
      • 2.1.2.2. Application segment outlook
      • 2.1.2.3. Therapeutic Area segment outlook
      • 2.1.2.4. Deployment Model segment outlook
      • 2.1.2.5. Pricing Model segment outlook
      • 2.1.2.6. End Use segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Rising prevalence of chronic diseases
      • 3.3.1.2. Growing demand for personalized medicine
      • 3.3.1.3. Technological advancements
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High cost associated with biosimulation technology and software
      • 3.3.2.2. Stringent regulatory requirements
    • 3.3.3. Market Opportunity Analysis
    • 3.3.4. Market Challenges Analysis
  • 3.4. U.S. Biosimulation Market Analysis Tools: PESTEL
    • 3.4.1. Political & Legal
    • 3.4.2. Economic & Social
    • 3.4.3. Technology
    • 3.4.4. Environmental
    • 3.4.5. Social
  • 3.5. Technology Trends
  • 3.6. Case Studies & Insights
  • 3.7. U.S. Biosimulation Market Analysis Tools: Porter's
  • 3.8. Covid-19 Impact Analysis

Chapter 4. U.S. Biosimulation Market: Offering Estimates & Trend Analysis

  • 4.1. U.S. Biosimulation Market: Offering Movement Analysis
  • 4.2. U.S. Biosimulation Market: Offering Segment Dashboard
  • 4.3. Offering Movement & Market Share Analysis, 2024 & 2030
  • 4.4. U.S. Biosimulation Market Estimates & Forecast, by Offering
  • 4.5. Software
    • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.2. Molecular Modeling & Simulation Software
      • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.3. Clinical Trial Design Software
      • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.4. PK/PD Modeling and Simulation Software
      • 4.5.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.5. Pbpk Modeling and Simulation Software
      • 4.5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.6. Toxicity Prediction Software
      • 4.5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.5.7. Other Software
      • 4.5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.2. Contract Services
      • 4.6.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.3. Consulting
      • 4.6.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
    • 4.6.4. Other (Implementation, Training, & Support)
      • 4.6.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Biosimulation Market: Application Estimates & Trend Analysis

  • 5.1. U.S. Biosimulation Market: Application Movement Analysis
  • 5.2. U.S. Biosimulation Market: Application Segment Dashboard
  • 5.3. Application Movement & Market Share Analysis, 2024 & 2030
  • 5.4. U.S. Biosimulation Market Estimates & Forecast, by Application
  • 5.5. Drug Discovery & Development
    • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.6. Disease Modeling
    • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 5.7. Other (Precision Medicine, Toxicology)
    • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. U.S. Biosimulation Market: Therapeutic Area Movement Analysis
  • 6.2. U.S. Biosimulation Market: Therapeutic Area Segment Dashboard
  • 6.3. Therapeutic Area Movement & Market Share Analysis, 2024 & 2030
  • 6.4. U.S. Biosimulation Market Estimates & Forecast, by Therapeutic Area
  • 6.5. Oncology
    • 6.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.6. Cardiovascular Disease
    • 6.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.7. Infectious Disease
    • 6.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.8. Neurological Disorders
    • 6.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 6.9. Others
    • 6.9.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 7. U.S. Biosimulation Market: Deployment Model Estimates & Trend Analysis

  • 7.1. U.S. Biosimulation Market: Deployment Model Movement Analysis
  • 7.2. U.S. Biosimulation Market: Deployment Model Segment Dashboard
  • 7.3. Deployment Model Movement & Market Share Analysis, 2024 & 2030
  • 7.4. U.S. Biosimulation Market Estimates & Forecast, by Deployment Model
  • 7.5. Cloud-based
    • 7.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 7.6. On-premise
    • 7.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 7.7. Hybrid Model
    • 7.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 8. U.S. Biosimulation Market: Pricing Model Estimates & Trend Analysis

  • 8.1. U.S. Biosimulation Market: Pricing Model Movement Analysis
  • 8.2. U.S. Biosimulation Market: Pricing Model Segment Dashboard
  • 8.3. Pricing Model Movement & Market Share Analysis, 2024 & 2030
  • 8.4. U.S. Biosimulation Market Estimates & Forecast, by Pricing Model
  • 8.5. License-based Model
    • 8.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.6. Subscription-based Model
    • 8.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.7. Service-based Model
    • 8.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 8.8. Pay Per Use Model
    • 8.8.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 9. U.S. Biosimulation Market: End Use Estimates & Trend Analysis

  • 9.1. U.S. Biosimulation Market: End Use Movement Analysis
  • 9.2. U.S. Biosimulation Market: End Use Segment Dashboard
  • 9.3. End Use Movement & Market Share Analysis, 2024 & 2030
  • 9.4. U.S. Biosimulation Market Estimates & Forecast, by End Use
  • 9.5. Life Sciences Companies
    • 9.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 9.6. Academic Research Institutions
    • 9.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)
  • 9.7. Others (CROs/CDMOs, Regulatory Authorities)
    • 9.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Company Market Position/Share Analysis, 2024
  • 10.3. Company Share Analysis
  • 10.4. Company Profiles/Listing
    • 10.4.1. Certara, USA.
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments
    • 10.4.2. Dassault Systemes
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments
    • 10.4.3. Advanced Chemistry Development
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments
    • 10.4.4. Simulation Plus
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments
    • 10.4.5. Schrodinger, Inc.
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments
    • 10.4.6. Chemical Computing Group ULC
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments
    • 10.4.7. Physiomics Plc
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments
    • 10.4.8. Rosa & Co. LLC
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments
    • 10.4.9. BioSimulation Consulting Inc.
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments
    • 10.4.10. Genedata AG
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments
    • 10.4.11. Instem Group of Companies
      • 10.4.11.1. Participant's Overview
      • 10.4.11.2. Financial Performance
      • 10.4.11.3. Product Benchmarking
      • 10.4.11.4. Recent Developments
    • 10.4.12. PPD, Inc.
      • 10.4.12.1. Participant's Overview
      • 10.4.12.2. Financial Performance
      • 10.4.12.3. Product Benchmarking
      • 10.4.12.4. Recent Developments
    • 10.4.13. Yokogawa Insilico Biotechnology GmbH
      • 10.4.13.1. Participant's Overview
      • 10.4.13.2. Financial Performance
      • 10.4.13.3. Product Benchmarking
      • 10.4.13.4. Recent Developments

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. biosimulation market revenue estimates and forecast, by offering, 2018 - 2030 (USD Million)
  • Table 4 U.S. biosimulation market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. biosimulation market revenue estimates and forecast, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6 U.S. biosimulation market revenue estimates and forecast, by deployment model, 2018 - 2030 (USD Million)
  • Table 7 U.S. biosimulation market revenue estimates and forecast, by pricing model, 2018 - 2030 (USD Million)
  • Table 8 U.S. biosimulation market revenue estimates and forecast, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S Biosimulation Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for Market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Type segment outlook
  • Fig. 11 Application segment outlook
  • Fig. 12 Distribution Channel segment outlook
  • Fig. 13 Competitive landscape
  • Fig. 14 U.S Biosimulation Market: Market dynamics
  • Fig. 15 U.S Biosimulation Market: Porter's analysis
  • Fig. 16 U.S Biosimulation Market: PESTLE analysis
  • Fig. 17 U.S Biosimulation Market: Offering segment dashboard
  • Fig. 18 U.S Biosimulation Market: Offering movement share analysis
  • Fig. 19 Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 20 Molecular Modeling & Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 21 Clinical Trial Design Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 22 PK/PD Modeling and Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 23 Pbpk Modeling and Simulation Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 24 Toxicity Prediction Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 25 Other Software Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 26 Services Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 27 Contract Services Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 28 Consulting Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 29 Other (Implementation, Training, & Support) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 30 U.S Biosimulation Market: Application segment dashboard
  • Fig. 31 U.S Biosimulation Market: Application Movement Share Analysis
  • Fig. 32 Drug Discovery & Development Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 33 Disease Modeling Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 34 Other (Precision Medicine, Toxicology) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 35 U.S Biosimulation Market: Therapeutic Area Segment Dashboard
  • Fig. 36 U.S Biosimulation Market: Therapeutic Area Movement Share Analysis
  • Fig. 37 Oncology Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 38 Cardiovascular Disease Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 39 Infectious Disease Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 40 Neurological Disorders Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 41 Others Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 42 U.S Biosimulation Market: Deployment Model Segment Dashboard
  • Fig. 43 U.S Biosimulation Market: Deployment Model Movement Share Analysis
  • Fig. 44 Cloud-based Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 45 On-premise Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 46 Hybrid Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 47 U.S Biosimulation Market: Pricing Model Segment Dashboard
  • Fig. 48 U.S Biosimulation Market: Pricing Model Movement Share Analysis
  • Fig. 49 License-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 50 Subscription-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 51 Service-based Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 52 Pay Per Use Model Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 53 U.S Biosimulation Market: End Use Segment Dashboard
  • Fig. 54 U.S Biosimulation Market: End Use Movement Share Analysis
  • Fig. 55 Life Sciences Companies Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 56 Academic Research Institutions Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 57 Others (CROs/CDMOs, Regulatory Authorities) Market Estimates & Forecasts, 2018 - 2030 (Revenue, USD Million)
  • Fig. 58 Company categorization
  • Fig. 59 Company Market position analysis, 2024
  • Fig. 60 Strategic framework